文献速递肿瘤 PET/CT甲状腺核医学

[99mTc]NM-01 SPECT/CT定量评估NSCLC中PD-L1表达的观察者间与观察者内一致性

Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer.
PubMed 文献 · EJNMMI Res · 2020-12-01

本研究分析了21例连续NSCLC参与者的[99mTc]NM-01 SPECT/CT研究,由三名独立观察者手动测量原发肺、转移灶及正常组织参考的ROImax,计算ICC并进行Bland-Altman分析。结果显示原发肺肿瘤/血池(T:BP)和淋巴结转移/血池(LN:BP)的观察者间ICC分别为0.83和0.87,观察者内ICC范围为0.95-0.97。结论认为[99mTc]NM-01 SPECT/CT定量评估具有良好的观察者间和观察者内一致性,可能可靠无创地评估PD-L1表达。

要点

  • T:BP观察者间ICC为0.83,LN:BP为0.87,一致性良好至优秀。
  • 手动ROImax再评分间隔42天,观察者内ICC范围为0.95-0.97。
  • [99mTc]NM-01 SPECT/CT有潜力可靠无创地评估NSCLC的PD-L1表达。

核心结论

  • [99mTc]NM-01 SPECT/CT定量评估在NSCLC中显示出良好至优秀的观察者间和观察者内一致性。
  • 包括与PD-L1状态相关的T:BP在内,[99mTc]NM-01 SPECT/CT有潜力可靠且无创地评估PD-L1表达。

研究设计与样本

  • 分析21例连续NSCLC参与者的[99mTc]NM-01 SPECT/CT研究,评估PD-L1表达。
  • 三名独立观察者手动测量原发肺、转移灶及正常组织参考的ROImax,包括注射后1小时和2小时共42个匿名研究。
  • 计算组内相关系数(ICC)并进行Bland-Altman图分析,确定观察者间和观察者内一致性。

主要发现

  • 原发肺肿瘤/血池(T:BP)观察者间ICC为0.83(95% CI 0.73-0.90)。
  • 淋巴结转移/血池(LN:BP)观察者间ICC为0.87(95% CI 0.81-0.92)。
  • 自由手ROImax的T(ICC 0.94)、LN(ICC 0.97)、肝脏(ICC 0.97)和血池(ICC 0.90)参考组织显示优秀的观察者间一致性。
  • 健康肺ROImax评分显示中等至优秀观察者间一致性(ICC 0.84),在主动脉弓水平一致测量时改善(ICC 0.89)。
  • 间隔42天后手动ROImax再评分T、LN、T:BP和LN:BP的观察者内一致性优秀(ICC范围0.95-0.97)。

临床怎么用

  • [99mTc]NM-01 SPECT/CT定量评估可用于NSCLC患者PD-L1表达的无创评估。
  • 手动ROImax测量方法在观察者间和观察者内具有良好至优秀的一致性,支持其临床应用的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Checkpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic and predictive biomarker for anti-PD-1/PD-L1 therapy. Technetium-99 m [99mTc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT quantification correlates with PD-L1 expression in NSCLC, presenting an opportunity for non-invasive assessment. The aim of this study was to determine the inter- and intraobserver agreement of the quantitative assessment of [99mTc]NM-01 SPECT/CT in NSCLC. METHODS: [99mTc]NM-01 SPECT/CT studies of 21 consecutive NSCLC participants imaged for the evaluation of PD-L1 expression were analysed. Three independent observers measured maximum counts in a tumour region of interest (ROImax) of primary lung, metastatic lesions and normal tissue references of both 1 and 2 h post-injection (n = 42) anonymised studies using a manual technique. Intraclass correlation coefficients (ICC) were calculated, and Bland-Altman plot analysis was performed to determine inter- and intraobserver agreement. RESULTS: Intraclass correlation of primary lung tumour-to-blood pool (T:BP; ICC 0.83, 95% CI 0.73-0.90) and lymph node metastasis-to-blood pool (LN:BP; ICC 0.87, 0.81-0.92) measures of [99mTc]NM-01 uptake was good to excellent between observers. Freehand ROImax of T (ICC 0.94), LN (ICC 0.97), liver (ICC 0.97) and BP (ICC 0.90) reference tissues also demonstrated excellent interobserver agreement. ROImax scoring of healthy lung demonstrated moderate to excellent interobserver agreement (ICC 0.84) and improved when measured consistently at the level of the aortic arch (ICC 0.89). Manual ROImax re-scoring of T, LN, T:BP and LN:BP using [99mTc]NM-01 SPECT/CT following a 42-day interval was consistent with excellent intraobserver agreement (ICC range 0.95-0.97). CONCLUSION: Good to excellent inter- and intraobserver agreement of the quantitative assessment of [99mTc]NM-01 SPECT/CT in NSCLC was demonstrated in this study, including T:BP which has been shown to correlate with PD-L1 status. [99mTc]NM-01 SPECT/CT has the potential to reliably and non-invasively assess PD-L1 expression. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier no. NCT02978196. Registered 30th November 2016.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Hughes DJ, Chand G, Goh V, et al. Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer. EJNMMI Res. 2020. PMID: 33259032. doi:10.1186/s13550-020-00734-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。